Herjan J.T. Coelingh Bennink

2026

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol.

Acta obstetricia et gynecologica Scandinavica ·doi:10.1111/aogs.70182

The introduction of oral GnRH antagonists has created the possibility to replace progestins in combined oral contraceptives as the suppressor of ovarian function. A concept for this new approach to oral hormonal contraception is the combina…

2025

Premature ovarian insufficiency and the risk of breast cancer.

Human reproduction open ·doi:10.1093/hropen/hoaf017

2025

The rediscovery of estetrol and its implications for estrogen treatment.

Menopause (New York, N.Y.) ·doi:10.1097/gme.0000000000002537

ObjectivesTo summarize the literature on the rediscovery and clinical exploration of the fourth natural estrogen estetrol (E4), more than 100 years after the discovery of estrone (E1), estradiol (E2), and estriol (E3).MethodsLiterature revi…

review 2024

Health benefits of combined oral contraceptives - a narrative review

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception ·doi:10.1080/13625187.2024.2317295

PURPOSE: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill. METHODS: We conducted a literature search for (review) articles that discussed the health benefits of combined oral c…

2021

Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.

European urology ·doi:10.1016/j.eururo.2021.08.003

article 2005

Mifepristone Is an Effective Oral Alternative for the Prevention of Premature Luteinizing Hormone Surges and/or Premature Luteinization in Women Undergoing Controlled Ovarian Hyperstimulation forin VitroFertilization

·doi:10.1210/jc.2004-1160

The present clinical study was conducted to investigate the effectiveness of a daily dose of 40 mg mifepristone in preventing premature LH surges in women undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization and t…

article 2001

Effects of tibolone on the endometrium

·doi:10.1080/cmt.4.3.203.208

OBJECTIVE: To investigate the effects of 24 months of tibolone treatment on the endometrium in postmenopausal women. DESIGN: An open, prospective, multicenter study with a treatment duration of 24 months. POPULATION: One hundred and fifty h…

article 1998

Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers

·doi:10.1016/s0010-7824(98)00053-5

The safety and tolerability as well as pharmacokinetics of a new selective antiprogestagen, Org 31710, were studied after oral administration of single doses of 10, 25, 50, or 75 mg to 24 healthy male volunteers. Per dose-group, five subjec…

article 1996

Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study

·doi:10.1016/s8756-3282(96)00219-0

The present randomized, double-blind, placebo-controlled, 2-year study is the first to evaluate the effect of 1.25 and 2.5 mg tibolone daily oral administration on trabecular and cortical bone loss in early postmenopausal women. Ninety-four…

article 1996

The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl)

Fertility and sterility ·doi:10.1016/s0015-0282(16)58096-0

ObjectiveTo assess whether tibolone can prevent the bone loss and symptomatic side effects normally associated with GnRH agonist (GnRH-a) use and whether tibolone modifies the effect of GnRH-a on endometriosis.DesignProspective, double-blin…